RESUMO
Background: Granuloma annulare (GA) is a common, benign, idiopathic inflammatory dermatosis. Aside from case reports and small studies, there are limited data about the characteristics of GA in children. Objective: This study aimed to better characterize the epidemiologic and clinical features, triggering factors, disease associations, and outcomes of GA in the pediatric population. Methods: We conducted a retrospective study of 73 pediatric patients diagnosed with GA at the University of Rochester Medical Center over a 7-year period. Results: The most common subtype was localized GA (71.2%, n = 52), followed by subcutaneous (also known as "deep GA"; 16.4%, n = 12) and generalized (12.3%, n = 9) subtypes. Over 90% of patients had idiopathic GA, with the remaining patients reporting viral infection or trauma as triggers. Half of the patients studied had comorbid conditions, most frequently atopic dermatitis (17.8%, n = 13), obesity (9.59%, n = 7), asthma (6.85%, n = 5), and allergic rhinitis (6.85%, n = 5). The median duration of the disease was 11.00 months (interquartile range (IQR) 15.75 months); generalized GA had the shortest duration (median 10.00 months, IQR 15.50 months), while subcutaneous GA had the longest duration (median 12.00 months and IQR 29.00 months). Although recurrence rates for subcutaneous and generalized GA were high at 45.5% and 33.3%, respectively, most patients achieved clearance or improvement with treatment. Conclusion: Most cases of GA in our study were idiopathic, with no clear differences between GA subtypes and associated comorbidities. Topical steroids were the most prescribed treatment with mixed efficacy.
RESUMO
Dermatologic reactions are among the most common adverse events of antiprogrammed cell death-1 (anti-PD-1) monoclonal antibodies agents and include maculopapular rash, psoriasiform rash, lichenoid eruptions, autoimmune bullous disorders, and vitiligo. Here, we present a case of a 12-year-old African American male with metastatic spitzoid melanoma treated with nivolumab who developed a mild lichenoid eruption that progressed to a severe case of lichen planus pemphigoides (LPP). Management was complex given the patient's age and history and included hospitalization for intravenous steroids, an intensive topical steroid regimen, methotrexate, and discontinuation of nivolumab. This case illustrates a rare but dramatic progression from a mild LP-like eruption to severe bullous lichenoid eruption, most consistent with LPP, as well as the diagnostic and treatment challenges in the setting of a pediatric patient on nivolumab.
Assuntos
Doenças Autoimunes , Exantema , Líquen Plano , Erupções Liquenoides , Melanoma , Dermatopatias Vesiculobolhosas , Humanos , Masculino , Criança , Nivolumabe/efeitos adversos , Líquen Plano/induzido quimicamente , Líquen Plano/diagnóstico , Erupções Liquenoides/induzido quimicamente , Melanoma/tratamento farmacológico , Exantema/induzido quimicamenteRESUMO
ABSTRACT: Cutaneous eruptions associated with hemophagocytic lymphohistiocytosis (HLH) have been reported in 6%-63% of patients. Clinical findings of these skin lesions vary widely and include maculopapular rashes, ulcers, and violaceous nodules. Corresponding histologic findings are also variable and are considered nonspecific. We report the case of a 4-year-old boy who initially developed a widespread popular-pustular rash 2 weeks after his 12-month measles, mumps, and rubella vaccinations. These resolved with scarring then recurred following his 24-month vaccinations. Multiple skin biopsies were negative for infectious organisms and showed a granulomatous infiltrate with perforation and necrobiosis. The differential diagnosis included perforating granuloma annulare, infection, or rheumatoid nodules. At the age of 4, he developed fever, hepatosplenomegaly, pancytopenia and other laboratory abnormalities, requiring hospitalization. A number of studies were performed including biopsies of bone marrow and liver. Molecular testing revealed 2 mutations in UNC13D known to be associated with familial HLH. His prior cutaneous lesions were likely caused by immune dysregulation exacerbated by immunizations because of underlying familial HLH. This case illustrates the importance of recognizing an unusual cutaneous manifestation of a rare disease to arrive at an earlier diagnosis in a pediatric patient. Although cutaneous eruptions usually develop concurrently with other systemic symptoms of HLH, preceding unusual skin lesions may be the first indication of this rare disease.
Assuntos
Toxidermias/genética , Linfo-Histiocitose Hemofagocítica/complicações , Proteínas de Membrana/genética , Vacinas/efeitos adversos , Pré-Escolar , Dermatite/patologia , Granuloma/patologia , Humanos , Linfo-Histiocitose Hemofagocítica/genética , Masculino , MutaçãoRESUMO
Background: Warts are a common dermatologic complaint with an increased incidence within the pediatric population. Warts are caused by multiple strains of the human papillomavirus (HPV). There is little research on how a patient's HPV immunization status affects the response to treatment of warts in pediatric patients. Aims: The purpose of this study is to investigate the relationship between HPV vaccination status and wart resolution. Materials and Methods: This is a retrospective chart review that investigates the relationship between response to routine treatment of warts and a subject's HPV vaccination status. Results: There was no significant relationship found between HPV vaccination status and resolution of warts (p = 0.797). However, there was a significant positive correlation between having the HPV vaccine and number of visits for the treatment of warts (r = 0.180, P = 0.024). Conclusion: This study did not show a significant correlation between HPV vaccination status and wart resolution, although it demonstrated a significant positive relationship between those immunized with the HPV vaccine and an increased number of treatment visits. Possible explanations for this unexpected correlation include the variation in HPV vaccine formulation, vaccination status, and frequency of office visits, since vaccinated patients are more likely to be compliant with office visits.
RESUMO
Late growth of infantile hemangiomas is an uncommon complication. We report three patients with segmental facial hemangiomas who experienced late growth and recurrent ulceration predominantly of the lower lip. These patients shared common clinical features including involvement of the S3 facial segment, oral and airway hemangiomas, and vascular anomalies associated with PHACE syndrome. This report highlights a clinical presentation at-risk for late growth and recurrent ulceration.
Assuntos
Hemangioma , Malformações Vasculares , Face , Hemangioma/complicações , Hemangioma/diagnóstico , Humanos , Lactente , SíndromeAssuntos
Fasciite/patologia , Fasciite/cirurgia , Imageamento por Ressonância Magnética/métodos , Sarcoma/patologia , Sarcoma/cirurgia , Pele/patologia , Biópsia por Agulha , Meios de Contraste , Diagnóstico Diferencial , Fasciite/diagnóstico por imagem , Seguimentos , Testa , Humanos , Imuno-Histoquímica , Lactente , Masculino , Sarcoma/diagnóstico por imagem , Resultado do Tratamento , Ultrassonografia Doppler/métodosRESUMO
The cause of PHACE syndrome is unknown. In a study of 218 patients, we examined potential prenatal risk factors for PHACE syndrome. Rates of pre-eclampsia and placenta previa in affected individuals were significantly greater than in the general population. No significant risk factor differences were detected between male and female subjects.
Assuntos
Coartação Aórtica/etiologia , Anormalidades do Olho/etiologia , Síndromes Neurocutâneas/etiologia , Coartação Aórtica/epidemiologia , Estudos Transversais , Anormalidades do Olho/epidemiologia , Feminino , Humanos , Recém-Nascido , Masculino , Síndromes Neurocutâneas/epidemiologia , Placenta Prévia , Pré-Eclâmpsia , Gravidez , Cuidado Pré-Natal/estatística & dados numéricos , Sistema de Registros , Fatores de Risco , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Most arteriovenous malformations (AVMs) are localized and occur sporadically. However, they also can be multifocal in autosomal-dominant disorders, such as hereditary hemorrhagic telangiectasia and capillary malformation (CM)-AVM. Previously, we identified RASA1 mutations in 50% of patients with CM-AVM. Herein we studied non-RASA1 patients to further elucidate the pathogenicity of CMs and AVMs. METHODS: We conducted a genome-wide linkage study on a CM-AVM family. Whole-exome sequencing was also performed on 9 unrelated CM-AVM families. We identified a candidate gene and screened it in a large series of patients. The influence of several missense variants on protein function was also studied in vitro. RESULTS: We found evidence for linkage in 2 loci. Whole-exome sequencing data unraveled 4 distinct damaging variants in EPHB4 in 5 families that cosegregated with CM-AVM. Overall, screening of EPHB4 detected 47 distinct mutations in 54 index patients: 27 led to a premature stop codon or splice-site alteration, suggesting loss of function. The other 20 are nonsynonymous variants that result in amino acid substitutions. In vitro expression of several mutations confirmed loss of function of EPHB4. The clinical features included multifocal CMs, telangiectasias, and AVMs. CONCLUSIONS: We found EPHB4 mutations in patients with multifocal CMs associated with AVMs. The phenotype, CM-AVM2, mimics RASA1-related CM-AVM1 and also hereditary hemorrhagic telangiectasia. RASA1-encoded p120RASGAP is a direct effector of EPHB4. Our data highlight the pathogenetic importance of this interaction and indicts EPHB4-RAS-ERK signaling pathway as a major cause for AVMs.
Assuntos
Malformações Arteriovenosas/diagnóstico , Malformações Arteriovenosas/genética , Capilares/anormalidades , Mutação em Linhagem Germinativa/genética , Sistema de Sinalização das MAP Quinases/fisiologia , Mancha Vinho do Porto/diagnóstico , Mancha Vinho do Porto/genética , Receptor EphB4/genética , Proteína p120 Ativadora de GTPase/genética , Bases de Dados Genéticas , Feminino , Estudo de Associação Genômica Ampla/métodos , Humanos , Masculino , LinhagemRESUMO
Blue rubber bleb nevus syndrome (Bean syndrome) is a rare, severe disorder of unknown cause, characterized by numerous cutaneous and internal venous malformations; gastrointestinal lesions are pathognomonic. We discovered somatic mutations in TEK, the gene encoding TIE2, in 15 of 17 individuals with blue rubber bleb nevus syndrome. Somatic mutations were also identified in five of six individuals with sporadically occurring multifocal venous malformations. In contrast to common unifocal venous malformation, which is most often caused by the somatic L914F TIE2 mutation, multifocal forms are predominantly caused by double (cis) mutations, that is, two somatic mutations on the same allele of the gene. Mutations are identical in all lesions from a given individual. T1105N-T1106P is recurrent in blue rubber bleb nevus, whereas Y897C-R915C is recurrent in sporadically occurring multifocal venous malformation: both cause ligand-independent activation of TIE2, and increase survival, invasion, and colony formation when expressed in human umbilical vein endothelial cells.
Assuntos
Neoplasias Gastrointestinais/genética , Predisposição Genética para Doença/epidemiologia , Mutação , Nevo Azul/genética , Receptor TIE-2/genética , Neoplasias Cutâneas/genética , Malformações Vasculares/genética , Bélgica , Estudos de Coortes , Feminino , Neoplasias Gastrointestinais/diagnóstico , Humanos , Incidência , Masculino , Nevo Azul/diagnóstico , Doenças Raras , Neoplasias Cutâneas/diagnóstico , Malformações Vasculares/diagnósticoRESUMO
PHACE syndrome represents the association of large infantile hemangiomas of the head and neck with brain, cerebrovascular, cardiac, ocular, and ventral or midline defects. Cardiac and cerebrovascular anomalies are the most common extracutaneous features of PHACE, and they also constitute the greatest source of potential morbidity. Congenital heart disease in PHACE is incompletely described, and this study was conducted to better characterize its features. This study of the International PHACE Syndrome Registry represents the largest central review of clinical, radiologic, and histopathologic data for cardiovascular anomalies in patients with PHACE to date. Sixty-two (41%) of 150 subjects had intracardiac, aortic arch, or brachiocephalic vessel anomalies. Aberrant origin of a subclavian artery was the most common cardiovascular anomaly (present in 31 (21%) of 150 subjects). Coarctation was the second most common anomaly, identified in 28 (19%) of 150 subjects, and can be missed clinically in patients with PHACE because of the frequent association of arch obstruction with aberrant subclavian origin. Twenty-three (37%) of 62 subjects with cardiovascular anomalies required procedural intervention. A greater percentage of hemangiomas were located on the left side of the head and neck in patients with coarctation (46% vs 39%); however, hemangioma distribution did not predict the presence of cardiovascular anomalies overall. In conclusion, PHACE is associated with a high risk of congenital heart disease. Cardiac and aortic arch imaging with detailed assessment of arch patency and brachiocephalic origins is essential for any patient suspected of having PHACE. Longitudinal investigation is needed to determine the long-term outcomes of cardiovascular anomalies in PHACE.
Assuntos
Aorta Torácica/anormalidades , Coartação Aórtica/epidemiologia , Tronco Braquiocefálico/anormalidades , Anormalidades do Olho/epidemiologia , Cardiopatias Congênitas/epidemiologia , Síndromes Neurocutâneas/epidemiologia , Sistema de Registros , Comorbidade , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Estudos Retrospectivos , Veia Subclávia/anormalidades , Grau de Desobstrução VascularRESUMO
Capillary malformation-arteriovenous malformation (CM-AVM) is an autosomal-dominant disorder, caused by heterozygous RASA1 mutations, and manifesting multifocal CMs and high risk for fast-flow lesions. A limited number of patients have been reported, raising the question of the phenotypic borders. We identified new patients with a clinical diagnosis of CM-AVM, and patients with overlapping phenotypes. RASA1 was screened in 261 index patients with: CM-AVM (n = 100), common CM(s) (port-wine stain; n = 100), Sturge-Weber syndrome (n = 37), or isolated AVM(s) (n = 24). Fifty-eight distinct RASA1 mutations (43 novel) were identified in 68 index patients with CM-AVM and none in patients with other phenotypes. A novel clinical feature was identified: cutaneous zones of numerous small white pale halos with a central red spot. An additional question addressed in this study was the "second-hit" hypothesis as a pathophysiological mechanism for CM-AVM. One tissue from a patient with a germline RASA1 mutation was available. The analysis of the tissue showed loss of the wild-type RASA1 allele. In conclusion, mutations in RASA1 underscore the specific CM-AVM phenotype and the clinical diagnosis is based on identifying the characteristic CMs. The high incidence of fast-flow lesions warrants careful clinical and radiologic examination, and regular follow-up.
Assuntos
Malformações Arteriovenosas/diagnóstico , Malformações Arteriovenosas/genética , Capilares/anormalidades , Mutação , Fenótipo , Mancha Vinho do Porto/diagnóstico , Mancha Vinho do Porto/genética , Proteína p120 Ativadora de GTPase/genética , Substituição de Aminoácidos , Análise Mutacional de DNA , Feminino , Ordem dos Genes , Estudos de Associação Genética , Humanos , Masculino , Estudos Prospectivos , Estudos RetrospectivosRESUMO
PHACE syndrome is the association of large segmental facial hemangiomas and congenital anomalies, such as posterior fossa malformations, cerebral arterial anomalies, coarctation of the aorta, eye anomalies, and sternal defects. To date, the reported cases of PHACE syndrome have been sporadic, suggesting that PHACE may have a complex pathogenesis. We report here genomic copy number variation (CNV) analysis of 98 individuals with PHACE syndrome as a first step in deciphering a potential genetic basis of PHACE syndrome. A total of 3,772 CNVs (2,507 duplications and 1,265 deletions) were detected in 98 individuals with PHACE syndrome. CNVs were then eliminated if they failed to meet established criteria for quality, spanned centromeres, or did not contain genes. CNVs were defined as "rare" if not documented in the database of genomic variants. Ten rare CNVs were discovered (size range: 134-406 kb), located at 1q32.1, 1q43, 3q26.32-3q26.33, 3p11.1, 7q33, 10q24.32, 12q24.13, 17q11.2, 18p11.31, and Xq28. There were no rare CNV events that occurred in more than one subject. Therefore, further study is needed to determine the significance of these CNVs in the pathogenesis of PHACE syndrome.
Assuntos
Coartação Aórtica/genética , Variações do Número de Cópias de DNA/genética , DNA/genética , Anormalidades do Olho/genética , Síndromes Neurocutâneas/genética , Adolescente , Adulto , Estudos de Casos e Controles , Criança , Pré-Escolar , Feminino , Técnicas de Genotipagem , Humanos , Lactente , Masculino , Reprodutibilidade dos Testes , Transdução de Sinais , Adulto JovemRESUMO
El síndrome de Adams-Oliver es un desorden congénito raro, caracterizado por la presencia de aplasia cutis congénita y defectos terminales transversos de los miembros. Comunicamos el caso de una niña de 4 años de edad con síndrome de Adams-Oliver que presenta venas congénitas, tortuosas y dilatadas en el cuero cabelludo, aplasia cutis congénita con defectos parciales del hueso craneal subyacente, calcificaciones intracraneales y anomalías leves de los pies.
Adams-Oliver syndrome is a rare congenital disorder characterized by aplasia cutis congenita and terminal transverse limb defects. We report a case of a 4-year-old girl with Adams-Oliver syndrome with congenital dilated and tortuous scalp veins, aplasia cutis congenita with partial underlying skull defects, intracranial calcifications, and mild foot anomalies.
Assuntos
Humanos , Feminino , Lactente , Couro Cabeludo/anormalidades , Displasia Ectodérmica/diagnóstico , Veias/anormalidades , Couro Cabeludo/patologia , Deformidades Congênitas das Extremidades Superiores/diagnóstico , Veias/patologiaRESUMO
BACKGROUND AND PURPOSE: PHACE is an acronym for posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Several case reports of arterial ischemic stroke (AIS) in individuals with PHACE have been published, but risk factors for AIS in PHACE have not been clearly defined. The objective of this article is to review all cases of stroke in PHACE in children and describe clinical characteristics that may be associated with an increased risk of AIS. METHODS: A literature and registry search was conducted to identify patients with PHACE who had experienced AIS. Data were analyzed to determine age of onset, presenting signs and symptoms, and clinical features among this cohort compared with PHACE without AIS. RESULTS: Twenty-two individuals with PHACE and AIS were identified. Imaging of the arteries of the head and neck was reported in 20 of 22. Narrowing or nonvisualization of at least 1 great cerebral vessel was present in 19 of 20 and of those, 15 had ≥ 2 vessels involved. Aortic arch anomalies were reported in 13 of 22 individuals. CONCLUSIONS: Aplasia, hypoplasia, or occlusion of a major cerebral artery appears to be a significant risk factor for AIS in children with PHACE, especially when >1 vessel is involved or if there is coarctation of the aorta.
Assuntos
Anormalidades Múltiplas/diagnóstico por imagem , Acidente Vascular Cerebral/diagnóstico por imagem , Acidente Vascular Cerebral/etiologia , Angiografia/métodos , Coartação Aórtica/complicações , Coartação Aórtica/diagnóstico por imagem , Encéfalo/anormalidades , Estudos de Coortes , Anormalidades do Olho/complicações , Anormalidades do Olho/diagnóstico por imagem , Feminino , Cardiopatias Congênitas/complicações , Cardiopatias Congênitas/diagnóstico por imagem , Hemangioma/complicações , Hemangioma/diagnóstico por imagem , Humanos , Lactente , Masculino , Fatores de Risco , SíndromeRESUMO
We report three infants who developed agminated pyogenic granulomas over congenital vascular malformations, all of which had an aggressive growth pattern. There were no precipitating events such as laser therapy or surgery. Lesions were excised.
Assuntos
Granuloma Piogênico/diagnóstico , Malformações Vasculares/diagnóstico , Feminino , Granuloma Piogênico/congênito , Granuloma Piogênico/patologia , Granuloma Piogênico/cirurgia , Humanos , Lactente , Masculino , Resultado do Tratamento , Malformações Vasculares/patologia , Malformações Vasculares/cirurgiaRESUMO
Introducción: Los hemangiomas son los tumores benignos más frecuentes de la infancia. La mayoría son lesiones tumorales localizadas, con bajo riesgo de complicaciones. Sin embargo, existe un grupo reducido de ellos (10 a 20%) que, durante la fase de crecimiento, puede ocasionar importante morbilidad, ya sea por ulceración, compromiso funcional por obstrucción de orificios naturales o porque producen una importante desfiguración cosmética. El tratamiento de primera línea para estos hemangiomas complicados son los corticoides sistémicos seguidos por vincristina o interferón alfa como drogas de segunda línea. El propranolol fue propuesto recientemente como una nueva opción terapéutica. Este trabajo describe nuestra experiencia en el tratamiento con propranolo de 33 pacientes con hemangiomas complicados, evaluados entre octubre de 2008 y octubre de 2009.Material y métodos: Fueron incluidos 33 pacientes (26 mujeres y 7 varones) con hemangiomas complicados, con edades entre 1 y 38 meses de vida. Se les administró propranolol oral a dosis de 2 mg/kg/día, dividido en 2-3 tomas. En todos los casos se obtuvo el consentimiento escrito de los padres. Al momento del ingreso en este protocolo fue realizada una evaluación clínica y cardiológica por un Pediatra y un Cardiólogo infantil. Durante el tratamiento se monitoreó la presión arterial y se hicieron electrocardiogramas repetidos. Resultados: Al inicio del tratamiento 27 pacientes eran menores de 1 año de vida, con edad media de 4,8 meses (rango: 1-11 meses). Los restantes 6 niños tenían 18, 20, 27, 36, 37 y 38 meses de edad. Treinta y uno de los 33 pacientes completaron el tratamiento, con una duración promedio de 4,5 meses (rango: 1 a 8 meses). Dos de ellos lo interrumpieron voluntariamente al no observar una respuesta significativa al mismo.
Introduction: Hemangiomas of infancy are the most common tumor of childhood. Although most children with hemangiomas have localized lesions with an uncomplicated course, a minority (10-20%) experience complications during the proliferative phase. Complications as ulceration, functional compromise due to obstruction of natural orifice or due to severe cosmetic desfigurement require treatment. The first line of treatment for these complicated hemangiomas is systemic corticosteroid and second line agents include vincristine or interferon alpha 2b. Propranolol was recently suggested as a therapeutic option for these hemangiomas. The present work reports our experience in the treatment of 33 patients with complicated hemangiomas with propranolol from October 2008 to October 2009. Materials and methods: Thirty-three patients (26 females and 7 males) with complicated hemangiomas, of 1 to 38 months of age, were included. Propranolol was given orally at a dose of 2 mg/kg/day, in 2-3 divided doses. In all cases informed consent was obtained from parents. At the moment of the inclusion in this protocol, a clinical and a cardiovascular evaluation was performed by a Pediatrician and a Pediatric Cardiologist. Electrocardiography and blood pressure were monitored during treatment. Results: Age at the beginning of treatment was less than 1 year old in 27 patients with an average age of 4.8 months (range: 1-11 months). The other 6 patients were 18, 20, 27, 36, 37 and 38 months old. Thirty-one of the 33 patients completed a 4.5 months average treatment (range: 1 to 8 months). Two of them voluntarily interrupted the treatment since they did not observe a significant response. Twenty-two patients showed quick response, with clinical evidence of regression during the first 2 weeks while the remaining 9 improved after 2 months of treatment. Just one patient showed an isolated episode of asymptomatic hypotension.